SEP-225289

SEP-225289
	File:SEP-225289 structure.png
Systematic (IUPAC) name
	(1R)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine
Identifiers
PubChem	CID 9900576
Chemical data
Formula	C15H22ClN
Molar mass	251.794 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

SEP-225,289 is an antidepressant drug derived from sibutramine, which is being developed by Sepracor and is currently in clinical trials. It is a so-called triple reuptake inhibitor (TRI)^[1]

Chemistry

Details for the synthesis of agents of this type were recently discovered: U.S. Patent 7,129,378

1-(4-chlorophenyl)cyclobutanecarbonitrile is reacted with i-BuMX in the first step.

See attachment for the ensuing reactions, which lie outside the scope of wikipedia.

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

35px	This drug article relating to the nervous system is a stub. You can help ssf by expanding it. v d e

↑ Chen, Z.; Skolnick, P. (2007). "Triple uptake inhibitors: therapeutic potential in depression and beyond". Expert opinion on investigational drugs. 16 (9): 1365–1377. doi:10.1517/13543784.16.9.1365. PMID 17714023. edit